Skip to main content
SpringerLink
Log in

Prevalence of the metabolic syndrome in moderately-severely obese subjects with and without growth hormone deficiency

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Background and aim: There is a considerable heterogeneity in metabolic phenotype among equally obese subjects. Impaired GH secretion is frequent in obese patients, with GH secretion reduced up to levels that are comparable to those found in adult patients with organic GH deficiency (GHD). Low GH status exerts detrimental effects on metabolic abnormalities in organic GHD patients. The aim of this observational, retrospective study was to investigate the prevalence of the metabolic syndrome (MetS) in moderately-severely obese subjects who met criteria for GDH (GHD) and in those with normal GH status (GH sufficient: GHS). Methods and results: One-hundred and ninety-five moderately-severely obese individuals partecipated, 149 women and 46 males [body mass index (BMI) 43.0±4.4 kg/m2 aged 34.3±11.8 yr]. Main outcome measures were: GH peak after GHRH plus arginine test, IGF-I, MetS parameters according to National Cholesterol Education Program criteria. Fifty-five subjects (27.3%) were GHD (49 females and 6 males). The prevalence of MetS parameters was 70.9% in GHD subgroup vs 52.9% in GHS (χ2=5.281; p=0.02) and the likelihood of MetS was highest in GHD subgroup (odds ratio: 2.174; 95% confidence interval 1.113 to 4.248). At the multiple regression analysis either GH peak or IGF-I were the major determinants of waist circumference (β=-0.380, t=−6.110 and β=-0.326, t=−4.704, respectively; p<0.001), while age and IGF-I were the major determinants of MetS (β=0.255, t= 3.342, and β=−0.282, t=−3.270; p=0.02, respectively). Conclusions: Among moderately-severely obese individuals the prevalence of the MetS was higher in GHD than in GHS subjects. Thus, in obese subjects, GH status investigation might be considered in the clinical evaluation of their metabolic risk profile.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000, 6: 697–738.

    Article  Google Scholar 

  2. Sims EA. Are there person who are obese, but metabolically healthy? Metabolism 2001, 50: 1499–504.

    Article  PubMed  CAS  Google Scholar 

  3. Guy-Grand B. From obesity to obesities: from concepts to practicies. Ann Endocrinol (Paris) 2003, 64: S7–15.

    CAS  Google Scholar 

  4. Wildman RP, Muntner P, Reynolds K, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med 2008, 168: 1617–24.

    Article  PubMed  Google Scholar 

  5. Després JP, Lemieux I, Bergeron J, et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008, 28: 1039–49.

    Article  PubMed  CAS  Google Scholar 

  6. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287: 356–9.

    Article  PubMed  Google Scholar 

  7. Bonora E, Kiechl S, Willeit J, et al; Bruneck Study. Metabolic syndrome: epidemiology and more extensive phenotypic description. Cross-sectional data from the Bruneck Study. Int J Obes Relat Metab Disord 2003, 27: 1283–9.

    Article  PubMed  CAS  Google Scholar 

  8. Bonora E. The metabolic syndrome: Is it still alive? In: G. Crepaldi, A. Tiengo, A. Avogaro eds. The metabolic syndrome: The road map from inflammation to cardiovascular disease. ICS1303. Amsterdam: Elsevier B.V. 2007, 2–9.

    Google Scholar 

  9. Visscher TL, Seidell JC. The public health impact of obesity. Annu Rev Public Health 2001, 22: 355–75.

    Article  PubMed  CAS  Google Scholar 

  10. Kopelman P. Health risks associated to overweight and obesity. Obes Rev 2007, 8: 13–7.

    Article  PubMed  Google Scholar 

  11. Björntorp P, Rosmond R. Neuroendocrine abnormalities in visceral obesity. Int J Obes Relat Metab Disord 2000, 24: S80–5.

    Article  PubMed  Google Scholar 

  12. Kokkoris P, Pi-Sunyer FX. Obesity and endocrine disease. Endocrinol Metab Clin North Am 2003, 32: 895–914.

    Article  PubMed  CAS  Google Scholar 

  13. Björntorp P. The regulation of adipose tissue distribution in humans. Int J Obes Relat Metab Disord 1996, 20: 291–302.

    PubMed  Google Scholar 

  14. Maccario M, Grottoli S, Procopio M, et al. The GH/IGF-I axis in obesity: influences of neuroendocrine and metabolic factors. Int J Obes Relat Disord 2000, 24: S96–9.

    Article  CAS  Google Scholar 

  15. Burt MG, Gibney J, Ho KK. Characterization of the metabolic phenotypes of Cushing’s syndrome and growth hormone deficiency: a study of body composition and energy metabolism. Clin Endocrinol (Oxf) 2006, 64: 436–43.

    Article  Google Scholar 

  16. Veldhuis JD, Iranmanesh A, Ho KK, Waters MJ, Johnson ML, Lizarralde G. Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man. J Clin Endocrinol Metab 1991, 72: 51–9.

    Article  PubMed  CAS  Google Scholar 

  17. Scacchi M, Pincelli AI, Cavagnini F. Growth hormone in obesity. Int J Obes Relat Metab Disord 1999, 23: 260–71.

    Article  PubMed  CAS  Google Scholar 

  18. Franco C, Bengtsson BA, Johannsson G. Visceral obesity and the role of the somatotropic axis in the development of metabolic complications. Growth Horm IGF Res 2001, 11: S97–102.

    Article  PubMed  Google Scholar 

  19. Pasquali R, Vicennati V, Gambineri A, Pagotto U. Hormones and pathophysiology of obesity. Eat Weight Disord 2001, 6 (3 Suppl): 9–20.

    PubMed  CAS  Google Scholar 

  20. Savastano S, Di Somma C, Mentone A, et al. GH insufficiency in obese patients. J Endocrinol Invest 2006, 29: 42–53.

    Article  Google Scholar 

  21. Corneli G, Di Somma C, Baldelli R, et al. The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. Eur J Endocrinol 2005, 153: 257–64.

    Article  PubMed  CAS  Google Scholar 

  22. Tanaka K, Inoue S, Numata K, Okazaki H, Nakamura S, Takamura Y. Very-low calorie diet-induced weight reduction reverses impaired growth hormone secretion response to growth hormone-releasing hormone, arginine, and L-dopa in obesity. Metabolism 1990, 39: 892–6.

    Article  PubMed  CAS  Google Scholar 

  23. Rasmussen MH, Hvidberg A, Juul A, et al. Massive weight loss restores 24-hour growth hormone release profiles and serum insulin-like growth factor-I levels in obese subjects. J Clin Endocrinol Metab 1995, 80: 1407–15.

    PubMed  CAS  Google Scholar 

  24. Maccario M, Valetto MR, Savio P, et al. Maximal secretory capacity of somatotrope cells in obesity: comparison with GH deficiency. Int J Obes Relat Metab Disord 1997, 21: 27–32.

    Article  PubMed  CAS  Google Scholar 

  25. Umpleby AM, Russel-Jones DL. The hormonal control of protein metabolism. Baillieres Clin Endocrinol Metab 1996, 10: 551–70.

    Article  PubMed  CAS  Google Scholar 

  26. Møller N, Gjedsted J, Gormsen L, Fuglsang J, Djurhuus C. Effects of growth hormone on lipid metabolism in humans. Growth Horm IGF Res 2003, 13: S18–21.

    Article  PubMed  CAS  Google Scholar 

  27. Colao A, Di Somma C, Savanelli MC, De Leo M, Lombardi G. Beginning to end: cardiovascular implications of growth hormone (GH) deficiency and GH therapy. Growth Horm IGF Res 2006, 16: S41–8.

    Article  PubMed  CAS  Google Scholar 

  28. Ho KK; GH Deficiency Consensus Workshop Participants. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol 2007, 157: 695–700.

    Article  PubMed  CAS  Google Scholar 

  29. Bengtsson BA, Johannsson G, Shalet SM, Simpson H, Sonken PH. Treatment of growth hormone deficiency in adults. J Clin Endocrinol Metab 2000, 85: 933–42.

    Article  PubMed  CAS  Google Scholar 

  30. Colao A, Di Somma C, Cuocolo A, et al. The severity of growth hormone deficiency correlates with the severity of cardiac impairment in 100 adult patients with hypopituitarism: an observational, case-control study. J Clin Endocrinol Metab 2004, 89: 5998–6004.

    Article  PubMed  CAS  Google Scholar 

  31. Beauregard C, Utz A, Schaub AE, et al. Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study. J Clin Endocrinol Metab 2008, 93: 2063–71.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  32. Albert SG, Mooradian AD. Low-dose recombinant human growth hormone as adjuvant therapy to lifestyle modifications in the management of obesity. J Clin Endocrinol Metab 2004, 2: 695–701.

    Article  CAS  Google Scholar 

  33. Johannsson G, Mårin P, Lönn L, et al. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab 1997, 82: 727–34.

    PubMed  CAS  Google Scholar 

  34. Franco C, Brandberg J, Lönn L, Andersson B, Bengtsson BA, Johannsson G. Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial. J Clin Endocrinol Metab 2005, 90: 1466–74.

    Article  PubMed  CAS  Google Scholar 

  35. Savastano S, Di Somma C, Belfiore A, et al. Growth hormone status in morbidly obese subjects and correlation with body composition. J Endocrinol Invest 2006, 29: 536–43.

    Article  PubMed  CAS  Google Scholar 

  36. Lamberts SW, de Herder WW, van der Lely AJ. Pituitary insufficiency. Lancet 1998, 352: 127–34.

    Article  PubMed  CAS  Google Scholar 

  37. Grundy SM, Cleeman JI, Daniels SR, et al; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112: 2735–52.

    Article  PubMed  Google Scholar 

  38. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997, 20: 1183–97.

    Google Scholar 

  39. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412–9.

    Article  PubMed  CAS  Google Scholar 

  40. Ghigo E, Aimaretti G, Gianotti L, Bellone J, Arvat E, Camanni F. New approach to the diagnosis of growth hormone deficiency in adults. Eur J Endocrinol 1996, 134: 352–6.

    Article  PubMed  CAS  Google Scholar 

  41. Colao A, Di Somma C, Cascella T, et al. Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: an observational, exploratory study in 404 subjects. Eur J Endocrinol 2008, 159: 389–97.

    Article  PubMed  CAS  Google Scholar 

  42. Corneli G, Di Somma C, Baldelli R, Rovere S, Gasco V, Croce CG. The cut-off limits of the GH response to GH-releasing hormonearginine test related to body mass index. Eur J Endocrinol 2005, 153: 257–64.

    Article  PubMed  CAS  Google Scholar 

  43. Abs R, Feldt-Rasmussen U, Mattsson AF, et al. Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults — a KIMS database analysis. Eur J Endocrinol 2006, 155: 79–90.

    Article  PubMed  CAS  Google Scholar 

  44. Johannsson G, Bengtsson BA. Growth hormone and the metabolic syndrome. J Endocrinol Invest 1999, 22 (5 Suppl): 41–6.

    PubMed  CAS  Google Scholar 

  45. Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 2008, 168: 1609–16.

    Article  PubMed  Google Scholar 

  46. Wolf AM, Buffington C, Beisiegel U. Comparison of metabolic risk factors between severely and very severely obese patients. Obesity (Silver Spring) 2006, 14: 2177–83.

    Article  Google Scholar 

  47. Girod JP, Brotman DJ. The metabolic syndrome as a vicious cycle: does obesity beget obesity? Med Hypotheses 2003, 60: 584–9.

    Article  PubMed  CAS  Google Scholar 

  48. Drapeau V, Lemieux I, Richard D, et al. Metabolic profile in severely obese women is less deteriorated than expected when compared to moderately obese women. Obes Surg 2006, 16: 501–9.

    Article  PubMed  Google Scholar 

  49. Kip KE, Marroquin OC, Kelley DE, et al. Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women’s Ischemia Syndrome Evaluation (WISE) study. Circulation 2004, 109: 706–13.

    Article  PubMed  Google Scholar 

  50. Pasquali R, Vicennati V, Cacciari M, Pagotto U. The hypothalamic-pituitary-adrenal axis activity in obesity and the metabolic syndrome. Ann N Y Acad Sci 2006, 1083: 111–28.

    Google Scholar 

  51. Utz AL, Yamamoto A, Hemphill L, Miller KK. Growth hormone deficiency by growth hormone releasing hormone-arginine testing criteria predicts increased cardiovascular risk markers in normal young overweight and obese women. J Clin Endocrinol Metab 2008, 93: 2507–14.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  52. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jørgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 2002, 106: 939–44.

    Article  PubMed  CAS  Google Scholar 

  53. Colao A, Spiezia S, Di Somma C, et al. Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy population independently of age. J Endocrinol Invest 2005, 28: 440–8.

    Article  PubMed  CAS  Google Scholar 

  54. Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB, Wareham NJ. Circulating concentration of insulin-like growth factor I and development of glucose intolerance: a prospective observational study. Lancet 2002, 359: 1740–5.

    Article  PubMed  CAS  Google Scholar 

  55. Maison P, Balkau B, Souberbielle JC, et al; D. E. S. I. R. Study Group. Evidence for distinct effects of GH and IGF-I in the metabolic syndrome. Diabet Med 2007, 24: 1012–8.

    Article  PubMed  CAS  Google Scholar 

  56. Marini MA, Succurro E, Frontoni S, et al. Metabolically healthy but obese women have an intermediate cardiovascular risk profile between healthy nonobese women and obese insulin-resistant women. Diabetes Care 2007, 30: 2145–7.

    Article  PubMed  Google Scholar 

  57. Makimura H, Stanley T, Mun D, You SM, Grinspoon S. The effects of central adiposity on growth hormone (GH) response to GH-releasing hormone-arginine stimulation testing in men. J Clin Endocrinol Metab 2008, 93: 4254–60.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. IRCCS SDN Foundation, University “Federico II” of Naples, Naples, Italy

    C. Di Somma

  2. Division of Endocrinology, Department of Molecular and Clinical Endocrinology and Oncology, University “Federico II” of Naples, via S. Pansini 5, 80131, Naples

    R. Pivonello, G. Pizza, A. De Rosa, G. Lombardi, A. Colao & S. Savastano MD, PhD

Authors
  1. C. Di Somma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Pivonello
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Pizza
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. De Rosa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. Lombardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Colao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. Savastano MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Savastano MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Di Somma, C., Pivonello, R., Pizza, G. et al. Prevalence of the metabolic syndrome in moderately-severely obese subjects with and without growth hormone deficiency. J Endocrinol Invest 33, 171–177 (2010). https://doi.org/10.1007/BF03346577

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03346577

Keywords

Search

Navigation